PMID- 23967328 OWN - NLM STAT- MEDLINE DCOM- 20140514 LR - 20220410 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 8 IP - 8 DP - 2013 TI - Association study of Val66Met polymorphism in brain-derived neurotrophic factor gene with clozapine-induced metabolic syndrome: preliminary results. PG - e72652 LID - 10.1371/journal.pone.0072652 [doi] LID - e72652 AB - The prevalence of the metabolic syndrome (MetS) is higher among patients receiving atypical antipsychotics (AAPs) treatment, and even among AAPs, treatment with clozapine has been shown to be associated with a higher long-term incidence rate of MetS. Likewise, brain-derived neurotrophic factor (BDNF) deficiency has been reported to result in metabolic traits, such as increased food intake, hyperphagia and obesity, etc. In this study, we hypothesized that a functional polymorphism (Val66Met) in the BDNF gene may confer susceptibility to clozapine-induced MetS, potentially in a sex-specific manner, since an interaction between Val66Met polymorphism and sex was observed in our previous studies. A total of 199 schizophrenia patients being treated with clozapine were divided into two groups, MetS and non-MetS, based on the diagnostic criteria of the National Cholesterol Education Program's Adult Treatment Panel III. We genotyped the Val66Met polymorphism, and measured the serum levels of fasting glucose (GLU), triglyceride (TG) and high density lipoprotein cholesterol (HDL). There was a trend indicating a significant association between the homozygous Met/Met genotype and MetS in male patients (OR = 2.39; 95% CI: 1.05-5.41; p = 0.039; corrected p = 0.078). Among the six risk factors listed in the ATPIII criteria, we found a significant association between fasting GLU levels and Val66Met polymorphism in males (p = 0.005; corrected p = 0.03), but not in females (p = 0.65). Post-hoc analysis in males revealed that the Met/Met carriers had significant higher levels of fasting GLU than those with Val/Val or Val/Met genotypes (p = 0.007; corrected p = 0.042 and p = 0.002; corrected p = 0.012, respectively). In conclusion, we observed a weak association between the Val66Met polymorphism and clozapine-induced MetS in a sex-specific manner. While preliminary, such findings prompt further, large-scale longitudinal studies to replicate these findings. FAU - Zhang, Yi AU - Zhang Y AD - Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Chen, Meijuan AU - Chen M FAU - Wu, Zhiguo AU - Wu Z FAU - Chen, Jun AU - Chen J FAU - Yu, Shunying AU - Yu S FAU - Fang, Yiru AU - Fang Y FAU - Zhang, Chen AU - Zhang C LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130813 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Codon) RN - 0 (Serotonin Antagonists) RN - J60AR2IKIC (Clozapine) SB - IM MH - Alleles MH - *Amino Acid Substitution MH - Brain-Derived Neurotrophic Factor/*genetics MH - Clozapine/adverse effects MH - *Codon MH - Cross-Sectional Studies MH - Female MH - Genetic Association Studies MH - Genotype MH - Humans MH - Male MH - Metabolic Syndrome/chemically induced/*genetics MH - Middle Aged MH - *Polymorphism, Single Nucleotide MH - Serotonin Antagonists/adverse effects PMC - PMC3742721 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2013/08/24 06:00 MHDA- 2014/05/16 06:00 PMCR- 2013/08/13 CRDT- 2013/08/23 06:00 PHST- 2013/05/20 00:00 [received] PHST- 2013/07/12 00:00 [accepted] PHST- 2013/08/23 06:00 [entrez] PHST- 2013/08/24 06:00 [pubmed] PHST- 2014/05/16 06:00 [medline] PHST- 2013/08/13 00:00 [pmc-release] AID - PONE-D-13-20783 [pii] AID - 10.1371/journal.pone.0072652 [doi] PST - epublish SO - PLoS One. 2013 Aug 13;8(8):e72652. doi: 10.1371/journal.pone.0072652. eCollection 2013.